Summary by Moomoo AI
Mangoceuticals, Inc. has announced a series of significant corporate events, including the issuance of Series B Convertible Preferred Stock and associated Warrants, an Equity Line of Credit (ELOC) agreement, and the acquisition of patents through the issuance of Series C Convertible Preferred Stock. The company has entered into a Securities Purchase Agreement (SPA) with an institutional accredited investor to sell Series B Preferred Stock and Warrants, potentially resulting in the issuance of more than 20% of the company's outstanding common stock. Additionally, the ELOC agreement with the same investor could see the sale of common stock up to $25 million, subject to stockholder approval. Mangoceuticals also acquired patents related to infection prevention from Intramont Technologies, Inc. in exchange for Series C...Show More